ImmunityBio Inc. has received a positive recommendation from the European Medicines Agency for conditional marketing authorization of its immunotherapy ANKTIVA (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin for the treatment of BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ. The recommendation positions ANKTIVA as the first immunotherapy in the European Union for this indication, offering a non-surgical treatment option for patients who currently face radical cystectomy as their primary alternative.

Why EMA’s support for ANKTIVA sets a regulatory precedent for high-need oncology settings

The European Medicines Agency’s recommendation is based on clinical data from a single-arm trial involving 100 adult patients with non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guérin therapy. This type of data package, while less robust than randomized controlled trials, was deemed sufficient under the agency’s conditional marketing authorization framework. That framework allows for earlier market access in cases where the benefit of a treatment’s immediate availability outweighs the risks of limited comparative evidence. The agency’s position signals growing regulatory flexibility in oncology, particularly for conditions where no approved alternatives exist and treatment delay could result in irreversible disease progression.

Unlike the traditional European Medicines Agency standard requiring randomized evidence, the decision to greenlight ANKTIVA under this accelerated path underscores the urgency regulators now attach to non-muscle invasive bladder cancer, especially the carcinoma in situ subtype. In this cohort, Bacillus Calmette-Guérin therapy often fails, and until now, there has been no authorized immunotherapy approved in Europe for such patients. The decision aligns with a trend toward tolerating greater evidentiary risk where the therapeutic risk of inaction is far higher.

What makes ANKTIVA mechanistically distinct from other bladder cancer immunotherapies

ANKTIVA is an interleukin-15 receptor agonist designed to activate and expand natural killer cells and T cells while generating memory T cells for long-term immune surveillance. When delivered intravesically with Bacillus Calmette-Guérin, ANKTIVA is intended to enhance local immune response while maintaining a favorable safety profile. The synergy is believed to improve the durability of response, particularly in a patient population that has failed prior Bacillus Calmette-Guérin treatment.

Unlike systemic checkpoint inhibitors such as pembrolizumab, which are approved for similar indications in the United States but associated with broader immune-related adverse events, ANKTIVA’s delivery is confined to the bladder. This localized mechanism of action offers a distinct safety and efficacy profile that could increase clinician comfort with its use earlier in the disease course. By preserving the bladder and reducing the need for radical cystectomy, the therapy introduces a bladder-sparing option with a different immune activation model than agents targeting PD-1 or PD-L1 pathways.

How regional BCG substrain availability in Europe could drive faster integration of the ANKTIVA protocol

One of the critical enablers for ANKTIVA’s deployment in Europe is the wider availability of Bacillus Calmette-Guérin substrains compared to the United States. While the United States only permits a single Bacillus Calmette-Guérin strain, the European Union authorizes approximately six, ensuring more robust and geographically resilient supply chains for this component of the combination therapy. This could help ImmunityBio sidestep the BCG-related supply constraints that have intermittently delayed therapy administration in the United States.

The importance of BCG access cannot be overstated. ANKTIVA’s efficacy is contingent upon its co-administration with BCG, and inconsistent access to BCG could limit real-world effectiveness. ImmunityBio has acknowledged this by advancing the development of its own recombinant BCG product, which is still under development. In the short term, however, the European landscape appears more conducive to uninterrupted treatment schedules, potentially accelerating ANKTIVA’s clinical adoption in select national health systems.

Why EMA’s clinical benefit-risk tradeoff matters for future bladder cancer development

The European Medicines Agency’s decision to recommend marketing approval based on a single-arm study represents a pivotal shift in how bladder cancer therapies may be evaluated moving forward. The trial reported a complete response rate of 71 percent, with responses lasting a median of 27 months. At the 12-month mark, 66 percent of responders remained cancer-free, and 42 percent maintained complete response at 24 months. While these results are encouraging, the absence of a control arm leaves some uncertainty about the degree of benefit attributable solely to ANKTIVA.

Nevertheless, the regulatory stance reflects a clear acknowledgment that, for patients with no viable therapeutic alternative, a well-characterized single-arm dataset can be sufficient if response durability and safety are acceptable. This decision could set a precedent for how regulators assess localized cancer immunotherapies, especially in urologic oncology, where trial recruitment is often challenged by surgical preference and the ethics of placebo control.

What risks and clinical tradeoffs remain in delaying cystectomy with ANKTIVA

Despite its promise, ANKTIVA carries a set of risks that regulators and clinicians alike continue to scrutinize. The most prominent concern is the potential for disease progression in patients who delay cystectomy while pursuing immunotherapy. Regulatory guidance in both the United States and Europe has highlighted the possibility that postponing surgical removal of the bladder may allow localized carcinoma in situ to progress into muscle-invasive or metastatic bladder cancer, which significantly worsens prognosis.

This risk underscores the need for careful patient selection and ongoing monitoring. The conditional marketing authorization requires ImmunityBio to provide long-term safety and efficacy data through post-marketing surveillance. For patients who do not respond after a second induction course, current practice guidance continues to recommend reconsideration of cystectomy. The therapy is therefore best positioned as an alternative for highly selected patients under close surveillance rather than a universal replacement for surgery.

What the pricing and reimbursement outlook could mean for ANKTIVA’s European launch

Commercially, ImmunityBio faces complex dynamics around pricing, especially in light of the United States’ Most-Favored-Nation policy that links drug pricing to international reference levels. ImmunityBio’s leadership has indicated that it is assessing its pricing and market access strategy carefully to ensure equitable but financially sustainable access across the European Union.

National health systems are expected to evaluate ANKTIVA’s price against existing options, including the surgical cost of cystectomy and the systemic expense of checkpoint inhibitors. However, the single-arm trial design could be a sticking point for value-based pricing frameworks in Europe. Payers may demand further data or real-world evidence before committing to broad coverage. Reimbursement pathways will likely vary widely across countries, with early uptake possibly concentrated in bladder cancer centers of excellence or tertiary care hospitals.

ImmunityBio’s pricing latitude may also be constrained by the conditional nature of the approval, which generally supports modest price anchoring relative to full authorization. This could delay or fragment its rollout unless additional confirmatory data bolsters the case for rapid national reimbursement approval.

What clinicians and regulators will watch for next as ImmunityBio moves toward EU launch

The next step is a final decision by the European Commission, which usually follows the European Medicines Agency recommendation within a two-to-three-month window. If granted, full marketing authorization will remain contingent on ImmunityBio fulfilling its post-approval obligations, including further safety data, real-world outcomes, and potential Phase 3 confirmation.

Clinicians are likely to monitor the rate of sustained response beyond 24 months and whether real-world performance aligns with trial outcomes. There will also be attention paid to recurrence rates, adverse events, and the time window between initial response and disease progression in non-responders. In addition, urologists may seek further clarity on which subsets of patients—by tumor burden, prior Bacillus Calmette-Guérin exposure, or molecular signature—derive the most durable benefit from ANKTIVA.

Regulators will remain attuned to ImmunityBio’s follow-through on long-term safety monitoring and timely submission of data. Any signs of suboptimal real-world efficacy or unexpected safety signals could jeopardize the conditional approval status and limit broader adoption.

If ImmunityBio succeeds in aligning BCG supply chains, confirming durable response patterns, and satisfying regulatory post-marketing requirements, ANKTIVA could emerge as a template for how future localized immunotherapies reach European patients—especially in diseases where the next-best option is life-altering surgery.

  ANKTIVA, BCG, bladder cancer treatment, conditional marketing authorization, EMA, IL-15 receptor agonist, ImmunityBio, immunotherapy, NMIBC, nogapendekin alfa inbakicept, non-muscle invasive bladder cancer, urologic oncology